Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anita Milicic

Dr


Principal Investigator, Vaccine Formulation and Adjuvants

  • Head of VFI-Oxford Adjuvant Programme
  • Jenner Institute Lead for Public Engagement

I studied Molecular Biology and Physiology at the University of Belgrade, Serbia, before completing MSc in Genetics and DPhil in Immunology at the University of Oxford.

In 2009 I joined the Jenner Institute in Oxford as the Head of the Adjuvant Facility, procuring and testing a range of novel vaccine adjuvants for human and veterinary application. I now lead the Vaccine Formulation and Adjuvants Group, studying immune mechanisms of vaccines and adjuvants, and developing novel vaccine formulations and delivery modalities.

My overall interest is in the processes of immune activation, in particular the interplay between the innate and the adaptive immunity, which we are exploring through a combination of in vitro and in vivo animal model systems and human ex vivo studies. We are taking an integrative spatio-temporal approach to understanding the adjuvant mechanisms of action, with the ultimate goal of improving vaccine efficacy.

Apart from research, I am involved in teaching within the University and externally (Milicic, A., Vaccination [Video file], Henry Stewart Talks: The Biomedical & Life Sciences Collection, 2021) and writing popular science articles on vaccination and vaccine adjuvants.

I am a Core Group member and Working Group leader in the EU COST Action Programme ENOVA (European Network of Vaccine Adjuvants). I am also the Jenner Institute Lead for Public Engagement with Research.